A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients

Exclusion Criteria

• •Participant had a partial or total splenectomy or infarcted areas of the spleen;
• •Participant had documented prior bleeding varices or liver infarction;
• •Participant received miglustat within 12 months prior to study enrollment;
• •The participant had received an investigational product within 30 days prior to study enrollment;
• •Participant had neurologic or pulmonary involvement;
• •Participant had new pathological bone involvement or bone crisis in the 12 months prior to enrollment;
• •Participant was transfusion-dependent;
• •Participant had a documented etiology of anemia due to causes other than Gaucher disease;
• •The participant had cardiac functional and/or anatomical abnormalities, a history of cancer or tested positive for human immunodeficiency virus (HIV) antibody or Hepatitis;
• •Participant had a clinically significant disease, other than Gaucher disease, including cardiovascular, renal, hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic, or psychiatric disease, other medical conditions, or serious intercurrent illnesses that, in the opinion of the Investigator, might preclude participation in the study.